| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| April 29, 2026 | ±2.1% | -0.0% | over-priced |
| November 5, 2025 | ±2.2% | +1.8% | over-priced |
| August 5, 2025 | ±3.8% | +2.3% | over-priced |
| May 7, 2025 | ±3.0% | -2.9% | over-priced |
| October 30, 2024 | ±1.9% | -2.3% | under-priced |
| August 1, 2024 | ±4.0% | -2.0% | over-priced |
| April 24, 2024 | ±1.9% | -3.5% | under-priced |
| October 26, 2023 | ±2.3% | +4.1% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $0.35 | $21.9B | $75M |
| Q4 FY2025 | $0.49 | $23.8B | $88M |
| Q3 FY2025 | $0.84 | $22.2B | $181M |
| Q2 FY2025 | $2.61 | $12.8B | $370M |
Bunge Global SA (BG) reports in 91 days, with the next report estimated for September 12, 2026. Across the last 8 reports, options priced an average ±2.7% earnings move while the stock actually moved 2.4% on average — the market has been roughly fair on BG's earnings risk. Fundamentals into the print: EPS down 76.4% year-over-year, revenue up 87.8%. QuantLogix's live 5-factor engine currently reads BG as a buy at 59/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →